Cigna Q2 Earnings Beat, Raises 2026 Outlook to at Least $30.45/Share
CI sits 22% above its 52-week low of $239.51.
Summary
Cigna reported Q2 2026 adjusted EPS of $7.78, up 8% year-over-year, and raised its full-year outlook to at least $30.45 per share, driven by strong performance in its health insurance segment.
Key Events · Earnings and Guidance · CI
-
Q2 Earnings Beat
Adjusted EPS of $7.78 vs. $7.20 a year ago, on revenue of $71.7B (+7% YoY).
-
Full-Year Guidance Raised
2026 adjusted EPS outlook increased to at least $30.45 from prior $30.35; Cigna Healthcare pre-tax income outlook raised by $25M to at least $4.55B.
-
Segment Performance
Cigna Healthcare pre-tax adjusted income rose 17% to $1.28B; Evernorth pre-tax adjusted income fell 2% to $1.66B due to client-focused investments.
-
Share Repurchases
Year-to-date through July 29, 2026, repurchased 0.9M shares for approximately $250M.
Analysis · CI · Finance
A strong second quarter saw revenue climb 7% to $71.7 billion, with adjusted EPS reaching $7.78—well above the prior-year's $7.20. Confidence in the diversified health services portfolio prompted management to lift the full-year 2026 adjusted EPS guidance to at least $30.45. The beat was fueled by Cigna Healthcare, where pre-tax adjusted income surged 17%, while Evernorth posted a modest decline tied to client-focused investments. These results underscore the company's ability to navigate a complex healthcare landscape, though pharmacy customer attrition and medical cost trends warrant monitoring.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CI was trading at $291.88 on NYSE in the Finance sector, with a market capitalization of approximately $78.4B. The 52-week trading range was $239.51 to $315.47. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.